SCHEMBL24573243

SCHEMBL24573243

O=C(O)c1ccc(-c2ccc3cc(O)ccc3c2)s1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.67
ERN1 O75460 1/20 0.59
MEN1 O00255 1/20 0.56
POLB P06746 1/20 0.56
RAB9A P51151 1/20 0.56
KMT2A Q03164 1/20 0.56
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
GAA P10253 1/20 0.51
HSD17B1 P14061 5/20 0.50
HSD17B2 P37059 5/20 0.50
NR4A2 P43354 1/20 0.50
RPS6KB2 Q9UBS0 1/20 0.48
ESR1 P03372 2/20 0.47
ESR2 Q92731 2/20 0.47
MKNK1 Q9BUB5 1/20 0.46
MKNK2 Q9HBH9 1/20 0.46
ESRRG P62508 1/20 0.46
PGR P06401 1/20 0.45
ABL1 P00519 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23110040 0.85 MEN1 (0.67) HPGDSERN1MEN1POLBRAB9A
SCHEMBL2083801 0.83 MEN1 (0.72) HPGDSMEN1POLBRAB9AKMT2A
SCHEMBL15293613 0.81 ESR1 (0.60) HPGDSERN1MEN1POLBRAB9A
SCHEMBL3639170 0.80 HPGDS (1.00) HPGDSMEN1POLBRAB9AKMT2A
SCHEMBL14156943 0.80 MEN1 (0.68) HPGDSMEN1POLBRAB9AKMT2A
SCHEMBL13335785 0.78 HSD17B1 (0.70) HPGDSHSD17B1HSD17B2ESR1ESR2
SCHEMBL1289509 0.77 ESR1 (0.51) HPGDSERN1MEN1POLBRAB9A
SCHEMBL22068905 0.77 POLB (0.68) HPGDSERN1MEN1POLBRAB9A
SCHEMBL5226359 0.76 APP (0.53) HPGDSHSD17B1HSD17B2ESR1ESR2
SCHEMBL6378961 0.76 RARB (0.61) HPGDSERN1MEN1POLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220202772-A1 COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2022-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220202772-A1 COMPOSITIONS AND METHODS FOR INHIBITING RIBOSOME INACTIVATING PROTEINS RACK1, RRBP1, RPL30 HPGDS 3257/4885ERN1 326/4885MEN1 4218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.